Background
==========

In recent years, much attention has been paid to the glycometabolism in patients with coronary artery disease (CAD). Numerous prior studies have shown that elevated admission or fasting glucose increases the risk of death and in-hospital complications in patients with acute coronary syndrome (ACS) and patients undergoing coronary revascularization \[[@B1]-[@B5]\].

Hemoglobin A~1c~(HbA~1c~) level is an indicator of average blood glucose concentrations over the preceding 2-3 months, which is a convenient and well-known biomarker in clinical practice. Epidemiological evidence now suggests that HbA1c level is an independent risk factor for cardiovascular events in primary and secondary populations \[[@B6]-[@B9]\]. Recently, an International Expert Committee Report (IECR) recommended using the HbA1c assay as the preferred method for diabetes diagnosis and suggested the diagnosis if the HbA1c level is ≥6.5% \[[@B10]\]. However, the prognostic value of HbA1c level in patients with coronary atherosclerotic disease has not been well characterized, and these studies that examined this relationship have reported conflicting results \[[@B11]-[@B23]\].

To comprehensively analyze these data, we performed a systematic review to examine whether an association exists between elevated HbA1c and all-cause mortality in patients hospitalized with CAD.

Methods
=======

The methods for this meta-analysis are in accordance with \"Meta-Analysis of Observational Studies in Epidemiology: A Proposal for Reporting.\" \[[@B24]\]

Search strategy
---------------

A systematic search of publications listed in the electronic databases (Medline via PubMed, EMBASE, OVID, Web of Science, The Cochrane Library) from 1970 to May 2011 were conducted using the following key words in combination as both MeSH terms and text words: (\"coronary artery disease\" or \"acute coronary syndrome\" or \"acute myocardial infarction\" or \"percutaneous coronary intervention\" or \"coronary artery bypass grafting\") and (\"glycated hemoglobin\" or \"hemoglobin A1c\" or \"HbA1c\"). Language restrictions were not applied, but our search was limited to human studies. The list of articles was reviewed independently by two authors. In addition, a manual review of references from primary or review articles was performed to identify any additional relevant studies

Study selection
---------------

Cohort, case-control studies, and randomized controlled trials were included if they investigated the influence of HbA1c on all-cause mortality in patients admitted with CAD. The IECR recommended that HbA~1c~level \> 6.5% would be the cut-off value for diagnosis of diabetes \[[@B10]\]. In patients with diabetes, the American Diabetes Association (ADA) recommended HbA~1c~\< 7% is associated with a lower risk of diabetes-associated complications \[[@B25]\]. We anticipated that not all studies would use HbA1c value 6.5% or 7% as the cut-off point. Therefore, in order to avoid eliminating studies with important information, we considered HbA1c cut-off within the range of 5% - 8% to be acceptable.

After obtaining full reports of candidate studies, the same reviewers independently assessed eligibility. Differences in data between the two reviewers were resolved by reviewing corresponding articles, and the final set was agreed on by consensus. If the publications did not contain the full information necessary for meta-analysis, we obtained the missing information directly from the authors (see Acknowledgments).

Quality assessment and data abstraction
---------------------------------------

Each study was evaluated for quality according to the guidelines provided by the United States Preventive Task Force \[[@B26]\] and published recommendations \[[@B27]\]. The following characteristics were assessed: (1) description of patient sample characteristics; (2) clear inclusion and exclusion criteria; (3) potential selection bias; (4) a priori definition of study outcomes; (5) completeness of follow-up; (6) adjustment of possible confounders in multivariate analysis; (7) explanation of sample selection; and (8) timing of determination (whether HbA1c measured at baseline). Studies were graded as poor quality if they met ≤4 criteria, fair if they met 5 to 6 criteria, and good if they met ≥7 criteria.

For each study, the following data were extracted: first author\'s last name, the publication year, study design, the sample size, study population, baseline characteristics, length of follow-up, timing of HbA1c measurement, cut-off value of HbA1c, variables adjusted for in the multivariate statistical analysis, mortality data among patients with and without elevated HbA1c level, and adjusted mortality hazard ratios (HRs) with their 95% CIs if possible.

Statistical analyses
--------------------

We used REVMAN software (version 5.0; Cochrane Collaboration, Oxford, United Kingdom) and Stata software (version 11.0; Stata Corporation, College Station, TX) to pool data for all outcomes. Firstly, unadjusted short and long term all-cause mortality data were extracted and pooled to calculate odds ratio (OR) and 95% CI using a random effects model for dichotomous outcomes. Relative risks were also calculated separately for diabetic and non-diabetic patients when possible. Secondly, we performed baseline risk-adjusted analyses to determine if our main results were robust when quantitative pooling was limited to those studies in which we could calculate pooled adjusted all-cause mortality ORs. Heterogeneity was assessed visually using Cochran\'s χ^2^statistics and the I^2^statistics. A random-effect model of DerSimonian and Laird was applied to calculate overall differences. Publication bias was estimated using a funnel plot of study results against study precision. We tested symmetry of the funnel plot using the Egger\'s test. P value was considered statistically significant at \< 0.05.

Results
=======

Study selection
---------------

Our initial search yielded 1883 potential literature citations. Of these, 1844 were excluded after scanning titles and abstracts, leaving 39 citations for full text assessment. Of these, 20 studies with a total of 13, 224 patients met the inclusion criteria and were used for this meta-analysis \[[@B13]-[@B23],[@B28]-[@B36]\]. The remaining studies were excluded largely because they did not include mortality as an outcome or did not provide mortality data according to HbA1c level; other subjects were included besides CAD patients; or reported HbA1c was in an unusable format (mean and SDs for patients with and without mortality). Additional data were requested from the authors of three studies \[[@B11],[@B12],[@B19]\] but obtained for only one study \[[@B19]\].

Characteristics of the trials
-----------------------------

Baseline characteristics of the 20 studies included are shown in Additional file [1](#S1){ref-type="supplementary-material"} and six studies were retrospective \[[@B19],[@B22],[@B28],[@B32],[@B33],[@B36]\]. We found no randomized controlled trial that examined the effect of HbA1c on mortality in patients admitted with CAD. Demographic features of study populations (age, gender) were similar across the studies, and the average age of the patients ranged from 56 to 75 years. The study population included 5258 patients (40%) admitted with AMI or ACS, 4948 (37.4%) patients who underwent CAGB and 2990 patients (22.6%) underwent PCI. Five of the 20 studies investigated short-term (less than 3 months) all-cause mortality \[[@B28]-[@B30],[@B34],[@B36]\], 13 studies reported long-term (1 year to 8 years) mortality \[[@B13]-[@B20],[@B22],[@B23],[@B32],[@B33],[@B35]\] and 2 studies with both short and long-term follow-up results \[[@B21],[@B31]\]. All studies were of high methodological quality (good or fair) (Additional file [1](#S1){ref-type="supplementary-material"}).

Table [1](#T1){ref-type="table"} shows baseline characteristics and treatment of the patients in original articles according to HbA1c level. As expected, patients with elevated HbA1c level had a higher prevalence of comorbidities including hypertension, heart failure, previous MI and renal insufficiency. Use of angiotensin-converting enzyme (ACE) inhibitors, β-blockers and lipid lowering drugs was higher in patients with elevated HbA1c compared to those with normal HbA1c level.

###### 

Baseline characteristics of the study population according to HbA1c

  ---------------------------------------------------------------------------------------------------------------------------------------
  Baseline Characteristics                                                    Patients With Elevated HbA1c   Patients With Normal HbA1c
  --------------------------------------------------------------------------- ------------------------------ ----------------------------
  Age (y), studies = 12, n = 10734                                            64                             65

  Male (%), studies = 12, n = 10734                                           64                             72

  History of Hypertension (%),\                                               74                             59
  studies = 10, n = 10242                                                                                    

  History of Heart failure (%),\                                              22                             14
  studies = 4, n = 5276                                                                                      

  Previous MI (%), studies = 3, n = 4219                                      48                             24

  Hyperlipidemia (%), studies = 3, n = 4149                                   36                             35

  Smoker (%), studies = 7, n = 3770                                           40                             41

  Body mass index (kg/m2), studies = 6, n = 2990                              27                             29

  Renal insufficiency (%), studies = 5, n = 5806                              10                             7

  β-Blocker (%), studies = 4, n = 3794                                        77                             77

  Angiotensin-converting enzyme (ACE) inhibitors (%), studies = 3, n = 1448   53                             39

  Lipid lowering drugs (%), studies = 4, n = 3794                             67                             41
  ---------------------------------------------------------------------------------------------------------------------------------------

Six studies \[[@B13],[@B16],[@B18],[@B21],[@B22],[@B28]\] exclusively examined non-diabetic patients, and the other six studies studied diabetes alone \[[@B14],[@B15],[@B32],[@B33],[@B35],[@B36]\], the percent of diabetic patients was not reported in two studies \[[@B19],[@B30]\] and the rest incorporated patients with and without diabetes \[[@B17],[@B20],[@B23],[@B29],[@B31],[@B34]\]. Diabetes status was assigned on the basis of a history of diabetes or treatment with hypoglycemic agents in 10 studies \[[@B14],[@B15],[@B17],[@B20],[@B23],[@B29],[@B31],[@B32],[@B34],[@B35]\]; in three of these studies, an elevated HbA1c \[[@B35]\] or plasma glucose \[[@B14],[@B17],[@B35]\] was also used to define newly diagnosed diabetes for patients without diabetes history. The definition of diabetes was not specified in two studies \[[@B33],[@B36]\].

HbA1c and risk of mortality
---------------------------

Nineteen studies reported all-cause mortality data according to HbA1c levels \[[@B13],[@B15]-[@B23],[@B28]-[@B36]\] (Figure [1](#F1){ref-type="fig"}). Analyses of the crude mortality revealed that 14.1% of patients with elevated HbA1c level died compared with 11.7% of those with normal HbA1c. This translated into an unadjusted mortality risk of OR 1.68 (95% CI, 1.38 to 2.06) in patients with elevated HbA1c. There was moderate statistical heterogeneity among the studies (I^2^= 49%, p \< 0.001). We found no evidence of publication bias based on funnel plot or using the Egger\'s test (P = 0.089). Subgroup analyses showed in the short-term follow up cohort, the elevated HbA1c level was associated with a more than two-fold increased risk of mortality (OR 2.32, 95% CI, 1.61 to 3.35), with no evidence for overall heterogeneity (I^2^= 0%, p = 0.48). Whereas patients with higher HbA1c level had a 54% increased risk of long-term mortality (OR 1.54, 95% CI, 1.23 to 1.94). And there was no significant difference between the short-term and long-term results (p = 0.06 for subgroup difference).

![**Unadjusted risk of short and long term mortality based on elevated or normal HbA1c level**.](1475-2840-10-98-1){#F1}

In addition, we performed a subgroup analyses to compare the association between HbA1c and mortality in patients with and without diabetes. These analyses were restricted to the 12 studies in which separate mortality data for diabetic and non- diabetic patients were reported \[[@B13],[@B15],[@B16],[@B18],[@B21]-[@B23],[@B28],[@B32],[@B33],[@B35],[@B36]\] (Figure [2](#F2){ref-type="fig"}). In patients without diabetes, elevated HbA1c was associated with a 84% increased risk of mortality (OR 1.84, 95% CI, 1.51 to 2.24). While in patients with diabetes, elevated HbA1c level was not associated with a significantly higher risk of mortality (OR 0.95, 95% CI, 0.70 to 1.28).

![**Unadjusted risk of mortality for patients with or without diabetes based on elevated or normal HbA1c level**.](1475-2840-10-98-2){#F2}

Risk adjusted analyses
----------------------

Eight studies used a Cox proportional hazards regression model to adjust for other prognostic factors to determine independent association of HbA1c with mortality \[[@B14],[@B15],[@B20]-[@B23],[@B34],[@B35]\] (Figure [3](#F3){ref-type="fig"}). All studies adjusted for age and gender. Other covariates adjusted for included diabetes \[[@B14],[@B20],[@B23]\], hypertension \[[@B14],[@B15],[@B22],[@B23]\], hyperlipidemia \[[@B14],[@B20],[@B22],[@B33]\], heart failure \[[@B14],[@B15],[@B22],[@B23]\], smoker \[[@B14],[@B15],[@B22],[@B23],[@B35]\], arrhythmia \[[@B22],[@B23]\], previous CAD \[[@B14],[@B15],[@B20],[@B22]\], multivessel disease \[[@B15],[@B20],[@B21]\], renal function \[[@B22],[@B23],[@B35]\], peripheral vascular disease \[[@B23]\], and study treatment \[[@B22]\]. In patients without diabetes, the pooled analyses suggested elevated HbA1c was independently associated with mortality after multivariate adjusted (adjusted OR 1.24, 95% CI, 1.01 to 1.54). In the three studies combined data for diabetic and nondiabetic patients, HbA1c level was also a predictor of mortality independent of other prognostic factors (adjusted OR 1.16, 95% CI, 1.03 to 1.30). But elevated HbA1c was not significantly associated with adjusted risk of death in diabetic patients (adjusted OR 1.05, 95% CI, 1.00 to 1.11). The overall pooled adjusted relative risk for elevated HbA1c was OR, 1.10 (95% CI, 1.03 to 1.17) for all the eight studies.

![**Adjusted mortality risk ratio for elevated HbA1c level**.](1475-2840-10-98-3){#F3}

Discussion
==========

The results of our meta-analysis suggest that elevated HbA1c levels predict increased risk of short and long term mortality in patients hospitalized with CAD. Subgroup analyses showed that the impact of HbA1c on mortality seemed to be different between patients with and without diabetes. Elevated HbA1c was associated with a higher risk of mortality in patients without recognized diabetes even after adjusting for other known risk factors, but had a neutral effect on mortality in patients with diabetes.

Diabetes mellitus and acute glycemic control (admission, fasting or preoperative glucose level) are independent prognostic factors for survival following ACS or AMI \[[@B1]-[@B5],[@B37],[@B38]\]. Although acute hyperglycemia for most patients may be a manifestation of antecedent disturbed glucose metabolism \[[@B1],[@B2]\], it is also partly caused by the transient stress with release of catecholamines and cortisol \[[@B39],[@B40]\]. The adverse outcomes associated with acute hyperglycemia may be somewhat attributed to the stress response to a severe disease state. HbA1c level is a stable indicator of unstressed long-term glucose control and is more useful to predict the abnormal glucose tolerance in CAD patients compared with admission glucose \[[@B41]\]. However, recent studies that evaluated the prognostic value of HbA1c in patients hospitalized with advanced atherosclerosis have reported discrepant results. Several studies showed that although crude mortality data was higher in patients with elevated HbA1c following adjustment for many cardiovascular risk factors, HbA1c values failed to predict mortality independently \[[@B11],[@B15],[@B16],[@B20],[@B30],[@B36]\]. Others suggested that HbA1c level was a potent predictor of in-hospital and long-term death \[[@B13],[@B14],[@B21],[@B23],[@B29],[@B31],[@B34]\]. After systematically reviewing previous published data and directly comparing the effect of HbA1 on outcomes in patients with and without recognized diabetes, we found that HbA1c levels had different prognostic effects based on patient\'s diabetes status.

There are several reasons for the discrepant findings between patients with and without diabetes. First, patients with elevated HbA1c but without known diabetes likely have diabetes that was neither diagnosed nor treated, and other relevant cardiovascular risk factors such as hypertension and dyslipidemia that were also untreated before hospitalization; while those with diabetes are more likely to be treated with insulin and control the established risk factors \[[@B2],[@B4]\]. This therapeutic difference may account in part for the disparity in outcomes. Second, the same cutoff value that defined elevated HbA1c may have been relatively too low to distinguish those with chronic hyperglycemia in diabetic patients compared with in non-diabetic patients. Third, recent studies suggested progress in the reperfusion treatment of patients with AMI improved the outcome of diabetic patients \[[@B42]\]. Effective reperfusion especially PCI might attenuate the adverse effect of elevated HbA1c on outcomes of diabetic patients \[[@B15]\]. Fourth, HbA1c may lose its predictive power in diabetic patients with heart failure as it has been recognized for other cardiovascular risk factors like BMI and total cholesterol \[[@B43]\]. A recent study reported the association between mortality and HbA1C among 5815 diabetic patients with heart failure appeared U-shaped, HbA1c ≤ 7.1 and \> 7.8% all associated with higher risk of death \[[@B44]\]. Another cohort study in diabetic patients with advanced heart failure observed an inverse relationship between HbA1c and long-term mortality \[[@B45]\]. Heart failure was present in \~20% of the diabetic patients included in our analysis. Future studies should investigate the impact of HbA1c in different high-risk diabetic populations with CAD. Fifth, the UK Prospective Diabetes Study (UKPDS) showed that although intensive glycemic treatment resulted in a non-significant improvement in macrovascular disease during the 5-year trial period \[[@B46]\], the 10-year follow-up demonstrated a significant risk reduction for myocardial infarction and death emerged over time \[[@B47]\]. The follow-up periods for diabetic patients in our study were all less than five years. Therefore, if the follow-up periods were longer, more differences in the mortality between diabetic patients with and without elevated HbA1c might have emerged.

Elevated HbA1c level is likely the result of long term insulin resistance; metabolic disturbances associated with insulin resistance including hyperglycemia, dyslipidemia, hypercoagulability and inflammation might the major pathologic mechanism for the adverse impact of elevated HbA1c in the setting of CAD \[[@B48]\]. In risk-adjusted analysis, after adjusted for other prognostic factors such as old age, hypertension, prior myocardial infarction, and hyperlipidaemia, HbA1c remained independently associated with increased mortality risk (except for patients with diabetes), but it was observed that the associations were attenuated. This suggested that the adverse effect of HbA1c on mortality is somewhat attributable to a correlation with other cardiovascular risk factors. The presence of an elevated HbA1c level, through its association with the metabolic syndrome, may potentially predate the development of other risk factors, and hence these risk factors may represent a common biological proatherogenic pathway \[[@B49],[@B50]\].

Prior clinical trials of intensive glucose control have shown little benefit, and possibly some harm, of lowering the HbA1c level in patients with diabetes to prevent cardiovascular outcomes \[[@B46],[@B47],[@B51],[@B52]\]. The results of two recent meta-analyses suggested that intensive glucose control reduced cardiovascular events with no effect on mortality \[[@B53],[@B54]\], and subgroup analyses showed participants with a history of cardiovascular disease did not appear to benefit from intensive therapy \[[@B54]\]. The majority of current trials for glycemic control were designed primarily to patients with established diabetes. Our observation support the need for large randomized trials designed to confirm or refute preliminary suggestions that intensive glycemic control may improve outcomes in CAD patients without diabetes and elevated HbA1c level.

Several limitations of this meta-analysis should be noted. First, the pooled studies differed in inclusion and exclusion criteria, cutoffs for elevated HbA1c, definition of diabetes, duration of follow-up and concomitant treatment. These may be the major source of heterogeneity. We used a random effects model in an effort to incorporate heterogeneity between trials in our analysis, but recognize that this does not eliminate the fact that heterogeneities were present. Second, given the lack of data in some studies, less than half the studies were combined for adjusted analysis, which meant that the results of risk-adjusted analysis were less conclusive. And the covariates adjusted in each study were different. Given the limitations, the results should be interpreted cautiously. Third, although we found no significant effect of elevated HbA1c on all-cause mortality in patients with diabetes, recent studies suggested that HbA1c was associated with an increased risk of major adverse cardiac events following stent implantation \[[@B55]\] and was a predictor of ischemic events in diabetic patients \[[@B56]\]. The prognostic effect of HbA1c on other cardiovascular events in diabetic patients with CAD needs further evaluation. Finally, given that a proportion of studies included are retrospective, a possibility of residual confounding by unmeasured factors cannot be eliminated. This provided associative, not causal, evidence and mandates caution when interpreting these results.

Conclusions
===========

In conclusion, we found that HbA1c level is an independent predictor of total mortality in CAD patients without but not in patients with established diabetes. Glycemic control, diabetes screening, and risk factor modification may represent opportunities to improve care in this group of patients.
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